COPENHAGEN, Denmark, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its second quarter 2024 financial results on Wednesday, August 14, 2024, before opening of the Nasdaq-CM. Evaxion’s Executive Management will host a conference call and webcast the same day at 14:30 CEST/08:30 EDT presenting the update and results as well a ...